Adult Respiratory Distress Syndrome
18
1
1
6
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
33.3%
6 terminated out of 18 trials
50.0%
-36.5% vs benchmark
6%
1 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (18)
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
Prevention of Lung Injury Induced by Mechanical Ventilation in Acute Respiratory Distress Syndrome ARDS Patients
Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19
Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19
Airway Pressure Release Ventilation (APRV) Compared to ARDSnet Ventilation
Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies
PaO2/FiO2*PEEP (P/FP) Ratio and Mortality in Acute Respiratory Distress Syndrome.
Tetracycline to Limit the Innate Immune Response in Acute Respiratory Distress Syndrome
Clinical Trial of Nebulized Hypertonic Saline to Attenuate Post-Traumatic Acute Lung Injury
Variable Pressure Support Trial
Acute Lung Injury Ventilator Evaluation (ALIVE)
Biomarkers of Lung Injury With Low Tidal Volume Ventilation Compared With Airway Pressure Release Ventilation
Assessing Respiratory Variability During Mechanical Ventilation in Acute Lung Injury (ALI)
Hyperoxia and Hypertonic Saline in Septic Shock
Simvastatin Effect on the Incidence of Acute Lung Injury/Adult Respiratory Distress Syndrome (ALI/ARDS)
Inhaled Prostacyclin for Adult Respiratory Distress Syndrome (ARDS) and Pulmonary Hypertension
Protective Ventilation With Carbon Dioxide (CO2) -Removal Technique in Patients With Adult Respiratory Distress Syndrome (ARDS)
ACE Gene Polymorphism and ARDS Outcome